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Approval of New Pharmacogenomic Tests: Is
the Canadian Regulatory Process Adequate?
Yann Joly, Emma Ramos-Paque*
INTRODUCTION
Pharmacogenomics and pharmacogenetics study the genetic factors behind in-
dividual variability in drug response.1 The idea is that certain genetic polymorph-
isms (i.e. differences in DNA sequence among individuals or populations) can de-
termine the way in which a person will respond to certain drugs.2 Whereas
pharmacogenetics is focused on the effects of single genes on drug response,
pharmacogenomics evaluates genetic variations across the entire genome.3 For the
sake of readability, the term “pharmacogenomics” will be used to refer to both
pharmacogenomics and pharmacogenetics.
Since its inception in the early 1950s,4 many hopes have been attached to
pharmacogenomic research because, in the clinical setting, variations among indi-
viduals in the efficacy and toxicity of drugs are common.5 Ultimately, pharmacoge-
nomic research will allow researchers to develop new drugs and modify existing
ones to better respond to genetic differences among patients. It will facilitate a
* Yann Joly, Ph.D. (DCL), Lawyer and Professional Associate, Centre of Genomics and
Policy, Faculty of Medicine, McGill University. Emma Ramos-Paque, LL.B., Lawyer
and Research Student, Centre of Genomics and Policy, Faculty of Medicine, McGill
University. Financial support for this research was primarily provided by Genome
Canada and Genome British Columbia. The authors would like to thank Bruce Carleton
and Michael Hayden from the CPNDS, Anne-Marie Tassé for her helpful comments
and Gregory Harris for his editorial assistance.
1 Nuffield Council on Bioethics, “Pharmacogenetics: Ethical Issues” (2003) at 94, on-
line: HumGen <http://www.humgen.org/virtual_library/1816_1/web/images/
1816.pdf>; Avinash Puri, “Pharmacogenomics: Benefits of Personalized Medicines”
(2009) 1:4 Int. J. Med. Med. Sci. 91 at 91.
2 Michel Eichelbaum, Magnus Ingelman-Sundberg and William E. Evans, “Pharmacoge-
nomics and Individualized Drug Therapy” (2006) 57 Annu. Rev. Med. 119 at 120.
3 Nuffield Council on Bioethics, supra note 1 at 94; Ann K. Daly, “Genome-Wide Asso-
ciation Studies in Pharmacogenomics” (2010) 11 Nat. Rev. Genetics 241 at 241; Scott
T. Weiss, Howard L. McLeod, David A. Flockhart, M. Eileen Dolan, Neal L. Be-
nowitz, Julie A. Johnson, Mark J. Ratain and Kathleen M. Giacomini, “Creating and
Evaluating Genetic Tests Predictive of Drug Response” (2008) 7 Nat. Rev. Drug Dis-
cov. 568 at 568.
4 M.V. Relling and J.M. Hoffman, “Should Pharmacogenomic Studies be Required for
New Drug Approval?” (2007) 81:3 Clinical Pharmacology & Therapeutics 425 at 425.
5 Grant R. Wilkinson, “Drug Metabolism and Variability among Patients in Drug Re-
sponse” (2005) 352:21 N. Engl. J. Med. 2211 at 2211.
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more accurate prediction of drug responses, reduce adverse drug reactions and al-
low for the personalization of drug therapy by allowing for the selection of a drug
or the determination of its dosage on the basis of the genotype of the patient.6
In Canada, the regulatory framework applicable to pharmacogenomic tests de-
pends on whether they fall within federal or provincial jurisdiction. As will be dis-
cussed, this depends on whether the tests are marketed as commercial kits or as
laboratory services. The two sets of regulations are quite different because they
have distinct objectives: whereas the federal regime is focused on the tests intended
to be sold or imported in Canada, the provincial process regulates laboratories.
For the manufacturer of a pharmacogenomic test, the federal process can be a
lengthy one because of all the evidence that must be provided. Fast tracking mecha-
nisms exist (such as the Special Access Program and the Priority Review), but, as
will be discussed, they are difficult to invoke in the context of pharmacogenomic
tests. From the perspective of patients and healthcare providers, pharmacogenomics
is seen as a tool that could be beneficial to patients and to the development of safer
and more efficient drugs. Thus, one question that arises in this field is whether the
current regulations inhibit the progress and the development of pharmacogenomic
tests and whether a fast track approval mechanism is warranted. Is the regulatory
framework adapted to the reality of pharmacogenomics?
In the first part of our analysis, we will examine the impact which
pharmacogenomics is expected to have on drug research and development, on the
drug approval process and on post-marketing surveillance and clinical practice.
This will allow us to show how pharmacogenomic testing could be beneficial to
drug companies, regulatory bodies, and patients. The second part of our analysis
will focus on the regulatory framework applicable to the approval of pharmacoge-
nomic tests in Canada, although we are aware of the fact that most manufacturers
decide to approve their tests outside of Canada. As mentioned, the applicable regu-
lations will depend on the way the test is marketed; the federal and provincial re-
quirements will both be covered in detail. It is interesting to note that very few
pharmacogenomic test developers currently choose to get their tests approved by
Health Canada. Most often they will commercialize their product in the United
States first and go through the provincial approval route when seeking approbation
in Canada.7
The review of the expected benefits and of the Canadian regulatory framework
governing pharmacogenomic tests will then allow us to evaluate if the latter is ap-
propriate considering the positive impact pharmacogenomics could have on phar-
maceutical development and the health care system. We will discuss the question of
whether it should be changed and simplified so that manufacturers could obtain
faster (or simplified) approval for their tests in order to commercialize them more
rapidly.
6 Amalia M. Issa, “Ethical Perspectives on Pharmacogenomic Profiling in the Drug De-
velopment Process” (2002) 1 Nat. Rev. Drug Discov. 300 at 300.
7 Leslie Tucker, “Pharmacogenomics: A Primer for Policymakers” National Health Pol-
icy Forum (28 January 2008) at 14, online: <http://www.nhpf.org/library/background-
papers/BP_Pharmacogenomics_01-28-08.pdf>.
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I. EXPECTED BENEFITS OF PHARMACOGENOMICS
Pharmacogenomics is expected to yield several benefits. In this section of our
analysis, we will look at those benefits from different perspectives, including those
of the pharmaceutical industry, the regulatory bodies, and patients. This section
will be relevant to the subsequent investigation of whether these anticipated bene-
fits are important enough to justify a change in the approval process applicable to
pharmacogenomic tests.
As will be discussed in this part of our analysis, among the benefits antici-
pated are the possibilities of improving drug research and development, making the
approval of new drugs faster and more efficient, improving drug efficacy and
safety, and tailoring treatment in clinical practice by allowing prediction of indivi-
dual response.
Pharmacogenomics can be used with the objective of reducing the incidence
of adverse events before patients experience them in the clinical practice setting.8
In this scenario, pharmacogenomic data are studied as the drug is being developed
to prevent adverse events in the clinical setting. Upon its release, the drug will be
marketed with the pharmacogenomic test.
Pharmacogenomics can also be used to identify and correlate genotypes with
drug responsiveness upon observation of adverse reactions. Thus, once a drug has
been developed and marketed, pharmacogenomic studies may be carried out when
adverse reactions have been noted among patients. Such studies will shed light on
differences in drug responsiveness among patients and permit researchers to corre-
late it with some polymorphisms to develop a test a posteriori.
(a) Impact on drug research and development
One of the major impacts expected is that pharmacogenomics will change the
way in which clinical drug trials are conducted and thereby change the drug devel-
opment process.9 Pharmacogenomics is believed to have the potential to affect
every stage of drug development, from the Preclinical Phase to Phase III.10
From an economic perspective, at the Preclinical Phase, it is expected that
8 Pharmacogenomic tests can be used either prospectively or retrospectively: Issa, supra
note 6 at 302.
9 Ibid. at 300.
10 Preclinical phase includes animal, in vitro and in vivo experiments designed to verify
the safety, therapeutic potential and toxicity of drug candidates: Trudo Lemmens and
Ron A. Bouchard, “Regulation of pharmaceuticals in Canada” in J. Downie, T. Caul-
field and C. Flood, eds., Canadian Health Law and Policy, 3d ed. (Toronto: But-
terworths, 2007) 318 at 321.
Phase I consists of initial safety studies on humans designed to provide information
about pharmacokinetics, pharmacodynamics, safety and side effects of the drug; Phase
II is conducted to evaluate the efficacy and side effects of the drug on patients affected
with the medical condition the drug is supposed to treat; Phase III is intended to gather
additional information about the efficacy and safety of the drug: Health Canada, Gui-
dance for clinical trial sponsors: Clinical Trial Applications (Guidance) (Ottawa: Min-
ister of Public Works and Government Services Canada, 2002) at section 2 [Health
Canada, CTA].
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pharmacogenomics could be used in the selection of drug candidates that will enter
clinical development, and which will be tested on humans in such a way that com-
pounds responsible for variable drug response and toxicity may be eliminated.11
But pharmacogenomics could also be used in a public health objective: during
Phase I of the clinical trials, pharmacogenomic testing could serve to reduce risk by
analyzing genetic differences in drug metabolism.12 However, the small number of
participants involved could make it difficult to prove any correlation.13 Neverthe-
less, because usually only healthy subjects are enrolled in Phase I trials,14 and be-
cause safety is a primary focus, pharmacogenomics could ensure that the partici-
pants selected are not put at an unnecessary risk.15 Individuals with particular
polymorphisms could be excluded from the study on the basis that they would not
benefit from it or would suffer adverse effects.16
Pharmacogenomics will likely be most useful during Phase II and Phase III
trials.17 Phase II trials mainly focus on establishing drug efficacy and short-term
side effects18 and, because they involve more volunteers than Phase I, the odds of
demonstrating a role for genetic variation in drug efficacy are greater.19 Identifying
genotypes that affect drug response in Phase II trials would enable more successful
Phase III trials that would be more efficient in size, time and cost.20 As a matter of
fact, Phase III trials are extremely expensive because they are conducted on a large
population sample21 to gather additional information about drug efficacy, safety,
and long-term side effects.22 The results from Phase I and II pharmacogenomic
11 Lawrence J. Lesko and Janet Woodcock, “Pharmacogenomic-Guided Drug Develop-
ment: Regulatory Perspective” (2002) 2 The Pharmacogenomics Journal 20 at 20
[Lesko and Woodcock, “Pharmacogenomic-guided”]; Laurent Essioux, Benoı̂t
Destenaves, Philippe Jais and François Thomas, “Association Studies in Pharmacoge-
nomics” in Julio Licinio and Ma-Li Wong, eds., Pharmacogenomics: The Search for
Individualized Therapies (Weinheim: Wiley-Vch, 2002) 57 at 74.
12 Karine Morin, “Canadian Legal Oversight of Pharmacogenomics and Nutrigenomics”
(2008) 16:3 Health L. Rev. 21 at 24.
13 Tilo Mandry, “Legal Implications of Pharmacogenomics Regarding Drug Trials, Drug
Labeling, and Genetic Testing for Drug Prescription: An International Approach”
(2004) 59 Food & Drug L.J. 519 at 526.
14 Unless it is unethical to do so: Health Canada, CTA, supra note 10 at section 2, s.v.
“Phase I”.
15 Barbara Ann Binzak, “How Pharmacogenomics Will Impact the Federal Regulation of
Clinical Trials and the New Drug Approval Process” (2003) 58 Food & Drug L.J. 103
at 119.
16 Mandry, supra note 13 at 526.
17 Yann Joly, “Biotechnologies et brevets : le cas de la pharmacogénomique” (2005) 10:2
Lex Electronica at 55, online: <http://www.lex-electronica.org/docs/articles_88.pdf>
[Joly, “Biotechnologies et brevets”].
18 Lemmens and Bouchard, supra note 10 at 322.
19 Mandry, supra note 13 at 526.
20 Joly, “Biotechnologies et brevets”, supra note 17 at 55.
21 Lemmens and Bouchard, supra note 10 at 322.
22 Ibid. at 322; Mandry, supra note 13 at 526.
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studies will help design an optimal Phase III trial,23 limited to individuals with a
high probability of responding well to the drug.24
Lowering costs and reducing time in drug development is a major issue today.
Drug research and development is a process involving a lot of time and resources.25
It has become essential for pharmaceutical companies to improve the success of
pharmaceutical research and development.26 Drug safety and efficacy are major
problems facing pharmaceutical companies that can lead to the rejection of their
submissions to Health Canada. Pharmacogenomic testing could be used to segment
the participants in two categories (responders and non-responders) on the basis of
their genetic profiles, so that non-responders are removed from the trial, instead of
stopping the development process of the compound.27 Pharmacogenomics would
also rescue compounds that fail in development because of adverse reactions.28 By
decreasing the incidence of non-responders and adverse drug responses, and requir-
ing fewer subjects and less time, pharmacogenomic testing could allow pharmaceu-
tical companies to obtain faster approval to market the drug and increase their
chances of success.29 Thus, pharmacogenomics is seen as a tool that could move
the development process from trial-and-error drug discovery towards rational drug
design30 by providing the ability to predict if a drug will succeed or fail in meeting
the safety and efficacy requirements early in the development process.31
23 Issa, supra note 6 at 304.
24 Lawrence J. Lesko, Ronald A. Salerno, Brian B. Spear, Donald C. Anderson, Timothy
Anderson, Celia Brazell, Jerry Collins, Andrew Dorner, David Essayan, Baltazar
Gomez-Mancilla, Joseph Hackett, Shiew-Mei Huang, Susan Ide, Joanne Killinger,
John Leighton, Elizabeth Mansfield, Robert Meyer, Stephen G. Ryan, Virginia
Schmith, Peter Shaw, Frank Sistare, Mark Watson and Alexandra Worobec,
“Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory De-
cision Making: Report of the First FDA-PWG-PhRMA-DruSafe Workshop” (2003) 43
J. Clin. Pharmacol. 342 at 352.
25 Joly, “Biotechnologies et brevets”, supra note 17 at 7; Jai Shah, “Concept and Putative
Application of Pharmacogenetics and Pharmacogenomics” (2004) 12:2 Health L. Rev.
3 at paras. 21-22 [Shah, “Concept and Putative”].
26 Lawrence J. Lesko and Janet Woodcock, “Translation of Pharmacogenomics and
Pharmacogenetics: A Regulatory Perspective” (2004) 3 Nat. Rev. Drug Discov. 763 at
763 [Lesko and Woodcock, “Translation”].
27 Allen D. Roses, “Pharmacogenetics and Drug Development: The Path to Safer and
More Effective Drugs” (2004) 5 Nat. Rev. Genetics 645 at 648.
28 Yann Joly, “La pharmacogénomique : perspective et enjeux éthico-juridiques” (2004)
9:3 Lex Electronica at 5, online: http://www.lex-electronica.org/docs/articles_99.pdf
[Joly, “La pharmacogénomique”]; Patricia A. Deverka, John Vernon and Howard L.
McLeod, “Economic Opportunities and Challenges for Pharmacogenomics” (2010) 50
Annu. Rev. Pharmacol. Toxicol. 423 at 428.
29 Lesko and Woodcock, “Translation”, supra note 26 at 763-764.
30 Shah, “Concept and Putative”, supra note 25 at paras. 21-22.
31 Lesko and Woodcock, “Translation”, supra note 26 at 764.
220   CANADIAN JOURNAL OF LAW AND TECHNOLOGY [8:2 C.J.L.T.]
(b) Impact on the Approval Process of Drugs
As stated above, pharmacogenomics could increase the chances of obtaining
market approval for a drug, because it minimizes the incidence of non-responders
and adverse drug reactions during clinical trials. It could also help obtain faster
approval by aiding in the assessment of the efficacy and safety of the compound
and by reducing the time allotted to the research and development of new drugs.
The importance of pharmacogenomics in the drug approval process is now even
more recognized by the fact that submission of pharmacogenomic data is en-
couraged when filing a new drug submission by guidelines adopted by Health Can-
ada (similar guidelines were adopted by the FDA in the United States).32 In our
opinion, the study of those guidelines is relevant to our analysis because they
demonstrate that obtaining pharmacogenomic data on new pharmaceutical drugs is
becoming increasingly important.
In Canada, Health Canada adopted in 2007 a Guidance Document on Submis-
sion of Pharmacogenomic Information.33 With this guidance document, Health
Canada recognized that the application of pharmacogenomics is becoming an inte-
gral part of the drug development process.34 Pharmacogenomic data will gradually
be submitted at different moments of the drug approval process to Health Canada:
first, during the application to start clinical trials and then when filing a New Drug
Submission.
In the Food and Drug Regulations,35 Parliament requires that the clinical trial
application for a new drug contain information on the pharmacological and
pharmacokinetic aspects of the drug, its toxicological effects, its safety and efficacy
and its dose responses.36 In accordance with this requirement, sponsors will be re-
quired to submit pharmacogenomic data if relevant to those questions.37 According
to Health Canada, pharmacogenomic data shall also be submitted as part of the
clinical trial application if they are used by the sponsor to support the design of the
proposed clinical trial, to justify human testing or to support the proposed labelling
of the drug.38
As for the new drug submission, sponsors shall comply with sections
C.08.002, C.08.002.1, and C.08.003 of the Food and Drug Regulations.39 Thus,
sponsors will have to submit pharmacogenomic data providing evidence of the
safety and clinical effectiveness of the new drug, or supporting the proposed dosage
32 Health Canada, Submission of Pharmacogenomic Information (Guidance) (Ottawa:
Public Works and Government Services Canada, 2008) at section 1.3 [Health Canada,
Submission of Pharmacogenomic]; U.S. Department of Health and Human Services,
Food and Drug Administration (FDA), Guidance for Industry: Pharmacogenomic Data
Submissions (March 2005) at 5 [FDA, Pharmacogenomic Data Submissions].
33 Health Canada, Submission of Pharmacogenomic, supra note 32.
34 Ibid. at section 1.1.
35 C.R.C., c. 870.
36 Ibid., s. C.05.005(e).
37 Health Canada, Submission of Pharmacogenomic, supra note 32 at section 2.1.
38 Ibid.
39 Food and Drug Regulations, supra note 35, ss. C.08.002, C.08.002.1, C.08.003.
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and contra-indications of the drug, as well as the claims to be made for the drug.40
Finally, if no pharmacogenomic test is available for use in Canada and if spon-
sors intend to use a pharmacogenomic test to support a therapeutic decision, like
the choice or dosing of a drug, Health Canada encourages them to apply for a li-
cence during the drug development process.41
In the United States, the Food and Drug Administration (FDA) also released,
in 2005, a guidance document on pharmacogenomic data submission to facilitate
the use of pharmacogenomic data in drug development.42 The FDA recognizes that,
for the moment, most pharmacogenomic data are of an exploratory or research na-
ture and thus does not require that they be submitted. It nevertheless encourages
voluntary submission, considering the benefits it brings to both the industry and the
FDA.43
Some authors are of the opinion that some degree of pharmacogenetic testing
should be required for new drug applications, because it should not be acceptable to
approve drugs without knowing if they are subject to variability due to common
germline variation.44 This review of the guidance on pharmacogenomic data sub-
mission demonstrates that pharmacogenomics is becoming more and more impor-
tant in the drug development and approval process. Thus, the appropriateness of the
regulatory framework applicable to pharmacogenomic testing could be questioned
if drug companies have to comply with stringent requirements to be able to use
pharmacogenomic tests during the drug development process (in part 2 of our anal-
ysis we will study those requirements and in part 3 we will discuss whether they are
too stringent).
Until now, we have examined the expected benefits of pharmacogenomic tests
at different phases before the commercialization of drugs. However, the impacts of
pharmacogenomics do not stop at the pre-marketing phase of the process.
Pharmacogenomics could also be very useful once the drug is marketed, whether it
is in post-marketing surveillance pharmacovigilance of adverse reactions or in the
daily practice of medicine.
(c) Impact in Post-Marketing Surveillance and in Clinical Practice
Although a drug can be sold in Canada once it has received marketing ap-
proval, studies on its efficacy and safety continue as post-marketing surveillance
pharmacovigilance. Indeed, post-marketing studies are often called Phase IV of the
drug development process. Those studies aim at identifying morbidity, mortality,
and adverse events.45 The role pharmacogenomics is likely to have at this post-
marketing phase is to provide a better understanding of the exact relationship be-
tween drug activity/toxicity and polymorphisms.46 Pharmacogenomic testing could
40 Health Canada, Submission of Pharmacogenomic, supra note 32 at section 2.2.
41 Ibid. at section 2.2.1.
42 FDA, Pharmacogenomic Data Submissions, supra note 32 at 1.
43 Ibid. at 7.
44 Relling and Hoffman, supra note 4 at 427.
45 Issa, supra note 6 at 303.
46 Essioux, Destenaves, Jais and Thomas, supra note 11 at 75.
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thus allow a superior surveillance of drugs on the market by enabling the assess-
ment of the population for whom the drug is best suited.47
In the daily practice of medicine, once a drug is brought to market, the hope
for pharmacogenomics is to allow true individualization of therapy by providing a
more precise diagnosis.48 Pharmacogenomic studies and testing could change the
way drugs are prescribed in the clinical setting, because the use of the drug could
be restricted according to genotypes.49 Pharmacogenomic tests could be given
before the prescription of drugs to determine whether a patient would have access
to a particular drug50 or to determine the appropriate dosage.51 Better choices for
drug therapies could help maximize the likelihood of efficacious treatment, mini-
mize the risk for adverse reactions52 and prevent drug withdrawal.
Thus, pharmacogenomics promises considerable benefits. From a better un-
derstanding of drug response mechanisms to a more streamlined drug development
and approval process, as well as the salvage of drugs that have been removed from
the market for safety reasons, pharmacogenomics offers the possibility for patients
to have access to safer, and more effective drugs and for pharmaceutical companies
to maximize their investments.53
Now that we have introduced the possible impacts of pharmacogenomics, we
will illustrate the situation by providing the example of Canadian Pharmacoge-
nomics Network for Drug Safety (CPNDS)/Cisplatin.
(d) The Case of CPNDS/Cisplatin
The example of Cisplatin offers a good illustration of the benefits
pharmacogenomics could provide. Cisplatin is a drug used for the treatment of
childhood malignancies, such as neuroblastomas and germ cell tumours.54 Cispla-
tin is one of the most ototoxic drugs used in oncology: it can cause permanent
47 Joly, “La pharmacogénomique”, supra note 28 at 6.
48 Lesko and Woodcock, “Pharmacogenomic-guided”, supra note 11 at 20.
49 Allen Buchanan, Andrea Califano, Jeffrey Kahn, Elizabeth McPherson, John Robert-
son and Baruch Brody, “Pharmacogenetics: Ethical Issues and Policy Options” (2002)
12:1 Kennedy Institute of Ethics Journal 1 at 2-3 [Buchanan, Califano, Kahn, McPher-
son, Robertson and Brody, “Ethical Issues”].
50 John A. Robertson, Baruch Brody, Allen Buchanan, Jeffrey Kahn and Elizabeth Mc-
Pherson, “Pharmacogenetic Challenges for the Health Care System” (2002) 21:4
Health Affairs 155 at 157 [Robertson, Brody, Buchanan, Kahn and McPherson,
“Pharmacogenetic Challenges”].
51 Joly, “La pharmacogénomique”, supra note 28 at 5.
52 Ibid. at 6; Brian B. Spear, Margo Heath-Chiozzi and Jeffrey Huff, “Clinical Applica-
tion of Pharmacogenetics” (2001) 7:5 Trends in Molecular Medicine 201 at 201.
53 Buchanan, Califano, Kahn, McPherson, Robertson and Brody, “Ethical issues”, supra
note 49 at 2.
54 L. Riedemann, C. Lanvers, D. Deuster, U. Peters, J. Boos, H. Jürgens and A. am
Zehnhoff-Dinnesen, “Megalin Genetic Polymorphisms and Individual Sensitivity to the
Ototoxic Effect of Cisplatin” (2008) 8 The Pharmacogenomics Journal 23 at 23.
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bilateral hearing loss in up to 25% of adults and 60% of children receiving it.55
This side effect often leads to dose reduction or premature termination of the treat-
ment which may affect overall survival rates or lead to learning difficulties for
children.56
The CPNDS project aims at establishing an active surveillance system for ad-
verse drug reactions in children and at promoting safe prescription medications by
identifying predictive biomarkers of drug risks.57 It is a $3.9 million project funded
by Genome BC and other funding partners.58 The CPNDS has been developing a
national database of clinical and genetic information relevant to the occurrence of
serious adverse drug reactions to identify genes associated with adverse drug reac-
tions in order to use those results to develop diagnostic tests that would allow per-
sonalized recommendations for commonly used drugs.59 In 2006, three adverse
drug reactions in children were targeted by the CPNDS for surveillance, one of
which was Cisplatin-induced hearing loss.60 The findings of CPNDS have, so far,
been very encouraging: researchers have identified genetic polymorphisms that are
associated with hearing loss following Cisplatin use.61 According to studies, two
single nucleotide polymorphisms are highly associated with Cisplatin-induced
55 Colin J.D. Ross, Hagit Katzov-Eckert, Marie-Pierre Dubé, Beth Brooks, S. Rod Ras-
sekh, Amina Barhdadi, Yassamin Feroz-Zada, Henk Visscher, Andrew M.K. Brown,
Michael J. Rieder, Paul C. Rogers, Michael S. Phillips, Bruce C. Carleton, Michael R.
Hayden and the CPNDS Consortium, “Genetic Variants in TPMT and COMP are As-
sociated With Hearing Loss in Children Receiving Cisplatin Chemotherapy” (2009)
4:12 Nat. Genetics 1345 at 1345.
56 Ibid.
57 “New Research Project Aims to Unlock Genetic Keys to Childhood ADRs and Help
Reduce Their Incidence”, Notes (2009) 142:2 CPJ/RPC 57; B.C. Carleton, R.L. Poole,
M.A. Smith, J.S Leeder, R. Ghannadan, C.J.D. Ross, M.S. Phillips and M.R. Hayden,
“Adverse Drug Reaction Active Surveillance: Developing a National Network in Can-
ada’s Children’s Hospitals” (2009) 18 Pharmacoepidemiology and Drug Safety 713 at
715.
58 Genome BC, “News releases: New research will help predict potentially fatal adverse
reactions to specific children’s drugs” (23 January 2009), online:
<http://www.genomebc.com/index.php?cID=341>.
59 Colin J.D. Ross, Bruce Carleton, Dana G. Warn, Sunita B. Stenton, Shahrad Rod Ras-
sekh and Michael R. Hayden, “Genotypic Approaches to Therapy in Children: A Na-
tional Active Surveillance Network (GATC) to Study the Pharmacogenomics of Severe
Adverse Drug Reactions in Children” (2007) 1110 Ann. N.Y. Acad. Sci. 177 at 180;
Turna Ray, “Genome BC project aims to launch PGx test to predict adverse drug reac-
tions in children” Pharmacogenomics Reporter (11 February 2009), online:
<http://www.genomeweb.com/dxpgx/genome-bc-project-aims-launch-pgx-test-predict-
adverse-drug-reactions-children>.
60 Genome British Columbia, “Genotype-Specific Approaches to Therapy in Childhood:
The Canadian Pharmacogenomics Network for Drug Safety”, online;
<http://www.genomebc.ca/portfolio/projects/health-projects/current/genotype-specific-
approaches-to-therapy-in-childhood-the-canadia/>; Carleton, Poole, Smith, Leeder,
Ghannadan, Ross, Phillips and Hayden, supra note 57 at 716.
61 S. Rod Rassekh, “Adverse events in pediatric oncology: The GATC Cancer Study”
(2007) 8 Pediatric Oncology Hematology Network Newsletter 3 at 4.
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deafness: one was found in the gene encoding thiopurine S-methyltransferase
(TPMT) and the other one in the gene encoding catechol O-methyltransferase
(COMT).62 Thus, it could become possible to identify individuals presenting a high
risk of developing hearing loss after receiving Cisplatin by genotyping patients
before giving the treatment.63 At risk patients would have the possibility of reduc-
ing their dose of Cisplatin or the possibility to be selected for experimental otopro-
tectant studies.64 The marketing of a pharmacogenomic test could then help pa-
tients avoid ototoxicity and consider alternative treatment options.
Now that we have introduced the possible impacts of pharmacogenomics on
the development of drugs, the drug approval process, the post-marketing surveil-
lance of drugs, and clinical practice, it is time to examine the requirements imposed
in Canada on manufacturers of pharmacogenomic tests.
II. REGULATORY FRAMEWORK APPLICABLE TO THE
APPROVAL OF PHARMACOGENOMIC TESTS IN CANADA
The Constitution Act, 186765 divides the power to legislate between the fed-
eral and provincial governments. According to this separation of powers,
pharmacogenomic tests control, or broadly speaking genetic tests control, falls
within both federal and provincial jurisdiction. Whether the federal or provincial
regulations apply to a pharmacogenomic test will depend on the marketing strategy
chosen by its provider.66 Whereas the control of laboratory services is devolved to
provinces as a consequence of their power in the management of health services,
the federal government will regulate the marketing and publicity of therapeutic
products within its competence over criminal matters.67
Only genetic tests sold as a test kit are subject to the federal provisions.68 A
test kit is defined in the federal legislation as an in vitro diagnostic device that
62 Ross, Katzov-Eckert, Dubé, Brooks, Rassekh, Barhdadi, Feroz-Zada, Visscher, Brown,
Rieder, Rogers, Phillips, Carleton, Hayden and the CPNDS Consortium, supra note 55
at 1346; Jacquelyn K. Beals, “Children’s hearing loss from Cisplatin chemotherapy
associated with gene variants” Medscape Medical News (20 November 2009), online:
<http://www.medscape.com/viewarticle/712849>.
63 Ross, Katzov-Eckert, Dubé, Brooks, Rassekh, Barhdadi, Feroz-Zada, Visscher, Brown,
Rieder, Rogers, Phillips, Carleton, Hayden and the CPNDS Consortium, supra note 55
at 1348.
64 Ibid.
65 Constitution Act, 1867 (U.K.), 30 & 31 Vict., c. 3, reprinted in R.S.C. 1985, App. II,
No. 5.
66 Mylène Deschênes, Réflexion sur l’encadrement normatif de la mise en marché des
tests génétiques (Montreal : Thémis, 2005) at 52-53.
67 Constitution Act, 1867, supra note 65, ss. 91(27), 92(7), 92(13), 92(16); See also Anne-
Marie Tassé and Béatrice Godard, “L’encadrement législatif de la vente directe des
tests génétiques et le système de santé québécois” (2007) 15 Health L.J. 441 at para. 9
[Tassé and Godard, “L’encadrement législatif”].
68 Medical Devices Regulations, S.O.R./98-282, s. 1; See also Tassé and Godard,
“L’encadrement législatif”, supra note 67 at para. 11.
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consists of reagents or articles intended to be used to conduct a specific test.69 Ex-
cluded from the definitions of “in vitro diagnostic device”, “near patient in vitro
diagnostic device” and “test kit”, are genetic tests offered as laboratory services.70
In order to illustrate the difference between a test kit and a laboratory service, con-
sider the following: if the patient has to take a sample of his DNA and send it to a
laboratory to analyze it, the test will be considered a laboratory service; however, if
the test is sold as a kit, where the sample is not sent to a laboratory because the
analysis is done by the patient (as it is the case for pregnancy tests) or by his or her
physician, then it will be considered a test kit. Therefore, if the test is marketed as
an in vitro diagnostic device, it will mostly be subject to federal control, whereas if
it is offered as a laboratory service, it will fall outside the scope of the federal
regulations and fall under provincial jurisdiction. The Canadian regulatory frame-
work applicable to genetic testing is not harmonized across the provinces and be-
tween the federal and provincial jurisdictions.71 As will be seen, only test kits fall-
ing under federal competence are required to be approved by Health Canada.
In the United States, contrary to “home-brew” tests, only test kits are regulated
by the FDA and are subject to pre-market approval.72 A home-brewed test is a test
developed and used by a laboratory “in-house” only, in contrast to a test developed
for sale and use outside the laboratory (test kit).73 Thus, the distinction in the
United States between “home-brewed test” and “test kit” is very similar to the dis-
tinction in Canada between “test kits” and tests offered as laboratory services. For
the moment, most pharmacogenomic tests are developed and approved in the
United States or in Europe, and are brought to the market as home-brews to avoid
having to go through a large portion of the regulatory process.74 It will be interest-
ing to keep this information in mind as we analyze the Canadian regulatory frame-
work, including the federal regulation applicable to tests marketed as test kits.
The fact that a pharmacogenomic test is manufactured as a test kit or as a
laboratory service does not directly impact its coverage by provincial health insur-
ance plans.75 The review of the applicable regulatory frameworks in Canada will
69 Medical Devices Regulations, supra note 68, s. 1, s.v. “test kit”.
70 Ibid., s. 1; Health Canada, Guidance for the Risk Based Classification System of In
Vitro Diagnostic Devices (Draft Guidance) (Ottawa: Therapeutic Products Programme,
1998) at section 2.2 [Health Canada, Guidance for the Risk].
71 Élodie Petit, Anne Marie Tassé and Béatrice Godard, “The Empirical Analysis of the
Legal Frameworks Governing Genetic Services Labs in Canadian Provinces” (2008)
16:3 Health L. Rev. 65 at 65 [Petit, Tassé and Godard, “Empirical Analysis”].
72 Louis P. Garrison Jr., Rick J. Carlson, Josh J. Carlson, Patricia C. Kuszler, Lisa M.
Meckley and David L. Veenstra, “A Review of Public Policy Issues in Promoting the
Development and Commercialization of Pharmacogenomic Applications: Challenges
and Implications” (2008) 40 Drug Metabolism Reviews 377 at 386; Tucker, supra note
7 at 14.
73 Gregorio M. Garcia, “The FDA and Regulation of Genetic Tests: Building Confidence
and Promoting Safety” (2008) 48 Jurimetrics 217 at 218.
74 Garrison Jr., Carlson, Carlson, Kuszler, Meckley and Veenstra, supra note 72 at 386.
75 For example, in Quebec, see the applicable legislation: Health Insurance Act, R.S.Q. c.
A-29; Regulation respecting the application of the Health Insurance Act, R.R.Q. 1981,
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allow us to evaluate if they are appropriate, or if they should be changed or simpli-
fied considering the benefits pharmacogenomic tests are likely to bring to drug
companies and patients.
(a) The Federal Regulations
At the federal level, Health Canada is the regulatory authority responsible for
evaluating the safety, efficacy, and quality of health products available in Canada,
including medical devices.76 Within Health Canada, it is the Therapeutic Products
Directorate that is responsible for granting market authorization for pharmaceutical
drugs and medical devices intended for human use in conformity with the provi-
sions of the Food and Drugs Act,77 the Food and Drugs Regulations78 and the
Medical Devices Regulations.79,80
According to the definitions set out in section 1 of the Medical Devices Regu-
lations and in section 2 of the Food and Drugs Act, a medical device is any article,
instrument or apparatus manufactured for use in the diagnosis, treatment, mitiga-
tion or prevention of a disease or its symptoms, in human beings.81 Pharmacoge-
nomic tests are considered medical devices because they are used with the intent of
choosing an effective treatment plan or the best suited drug for a patient, and thus
are themselves part of the treatment.82 More precisely, pharmacogenomic tests are
in vitro diagnostic devices.83 Thus, pharmacogenomic tests are regulated by the
Therapeutic Products Directorate’s Medical Devices Bureau in accordance with the
Food and Drugs Act and the Medical Devices Regulations.84
At the federal level, the Medical Devices Regulations set out the requirements
governing the sale of pharmacogenomic tests. Its goal is to ensure that medical
c. A-29, r. 1; Hospital Insurance Act, R.S.Q. c. A-28; Regulation respecting the appli-
cation of the Hospital Insurance Act, R.R.Q. 1981, c. A-28, r. 1; Régie de l’assurance
maladie, Medical Services — Services covered, online: <http://www.ramq.gouv.
qc.ca/en/citoyens/assurancemaladie/serv_couv_queb/serv_med_sc.shtml>; Régie de
l’assurance maladie, Medical Services — Services not covered, online:
<http://www.ramq.gouv.qc.ca/en/citoyens/assurancemaladie/serv_couv_queb/serv_
med_snc.shtml>.
76 Health Canada, Submission of Pharmacogenomic, supra note 32 at section 2.0.
77 R.S.C. 1985, c. F-27.
78 Supra note 35.
79 Supra note 68.
80 Ron A. Bouchard and Monika Sawicka, “The Mud and the Blood and the Beer: Can-
ada’s Progressive Licensing Framework For Drugs Approval” (2009) 3 McGill J.L. &
Health 49 at 54.
81 Medical Devices Regulations, supra note 68, s. 1; Food and Drugs Act, supra note 77,
s. 2.
82 Deschênes, supra note 66 at 54.
83 Medical Devices Regulations, supra note 68, s. 1, s.v. “in vitro diagnostic device”.
84 Health Canada, Submission of Pharmacogenomic, supra note 32 at section 2.0.
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devices distributed in Canada are safe and effective and meet quality standards.85
Sections 10 to 20 enumerate the general safety and effectiveness requirements ap-
plicable to all medical devices, except devices sold for custom or special access
purposes and for investigational testing purposes.86 Among others, section 12 re-
quires that the medical device perform as intended, and be effective for the pur-
poses and uses for which it is manufactured, sold or represented.87 Requirements in
sections 10 to 20 focus on the physical safety of the test and its reliability (i.e., its
analytical validity, or the accuracy with which the genetic polymorphism can be
identified in the test).88 Beside those general requirements, medical devices
presenting a higher level of risk are subject to additional standards that will vary
according to the importance of the risk associated with the device. Under section 6
of the Medical Devices Regulations, medical devices are classified into one of
Classes I to IV, where Class I represents the lowest risk and Class IV represents the
highest risk.89 With the exception of Class I medical devices, prior to marketing a
medical device in Canada, the manufacturer has to obtain a licence from the Medi-
cal Devices Bureau of Health Canada, which will determine whether the device
meets the safety and effectiveness requirements.90
To determine the class to which a medical device belongs, the Medical De-
vices Bureau will examine its intended use, application, instructions for use, the
technical, scientific or medical expertise needed for its use, the importance of the
information to the diagnosis, and the impact of the result on the individual.91 The
classification rules are set out in Schedule 1 of the Medical Devices Regulations.
Genetic tests in general are classified as Class III medical devices.92 Health Canada
stated that, in Canada, all devices intended to be used for pharmacogenomic testing
were also Class III medical devices.93 Class III medical devices are considered to
present either a moderate public health risk or a high individual risk.94
Section 32 of the Medical Devices Regulations indicates the information that
an application for a new Class III medical device shall contain in order to obtain a
licence from Health Canada.95 The application must contain the name, class, and
identifier of the device, as well as information about its manufacturer and the estab-
85 Health Canada, Preparation of a Premarket Review Document for Class III and Class
IV Device/Licence Applications (Guidance) (Ottawa: Therapeutic Products Programme,
1998) at section 1.2 [Health Canada, Premarket Review Document].
86 Medical Devices Regulations, supra note 68, ss. 10–20; Health Canada, Preparation of
an Application for Investigational Testing: In Vitro Diagnostic Devices (IVDD) (Gui-
dance) (Ottawa: Therapeutic Products Programme, 1999) at section 1.1 [Health Can-
ada, Investigational Testing].
87 Medical Devices Regulations, supra note 68, s. 12.
88 Ibid., ss. 10–20.
89 Ibid., s. 6.
90 Ibid., s. 26.
91 Health Canada, Guidance for the Risk, supra note 70 at section 3.
92 Medical Devices Regulations, supra note 68, Sch. I, part 2, rule 4(b).
93 Health Canada, Submission of Pharmacogenomic, supra note 32 at section 2.2.1.
94 Health Canada, Guidance for the Risk, supra note 70 at section 3.
95 Medical Devices Regulations, supra note 68, s. 32.
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lishment where the device is being manufactured. Also, it shall include: a descrip-
tion of the device and the features of the device that permit it to be used for the
purposes and uses for which it is sold; a list of the countries where the device has
been sold and a summary of any reported problems; a list of the standards complied
with in the design and manufacturing of the device to satisfy the safety and effec-
tiveness requirements; and a summary of all studies on which the manufacturer
relies to ensure the safety and efficacy of the device (all preclinical physical testing,
preclinical studies, and previous clinical investigations).96 The manufacturer must
present a bibliography of all published reports dealing with the use, safety and ef-
fectiveness of the device as well as a copy of the quality management system certif-
icate attesting that the system under which the device is designed and manufactured
satisfies the requirements of National Standard of Canada CAN/CSA-ISO
13485:03. Another relevant requirement is that the manufacturer has to submit a
summary of investigational testing conducted on the device using human subjects
representative of the intended users and under conditions similar to the conditions
of use. This requirement is only applicable in the case of a near patient in vitro
diagnostic device, which consists of an in vitro diagnostic device intended for use
outside a laboratory for testing at home or at a point of care.97 Pharmacogenomic
tests sold as test kits correspond to the definition of a near patient in vitro diagnos-
tic device, which means that the manufacturer will have to conduct investigational
testing and that, prior to making a licence application, it will have to apply for an
investigational testing authorization (this process will be studied later on).
The submitted evidence on safety and effectiveness will then undergo a scien-
tific and medical review before the licence application can be authorized.98 The
federal regulatory process applicable to the approval of pharmacogenomic test is
focused on the safety and efficacy of tests. There has to be scientific and medical
evidence that the test will perform as intended and as represented to the public. The
test must present strong analytical and clinical validity99 as well as clinical util-
ity100 before Health Canada can issue a licence to the manufacturer allowing its
sale or importation in Canada. Hence the need imposed by section 32(3)(h) to con-
duct investigational testing on subjects representative of the intended users and
under conditions similar to the conditions of use.101 These requirements ensure that
Health Canada will meet its mandate to evaluate the health-related risks and bene-
fits of health products and food and to minimize health risk factors of Canadians
while maximizing the safety and promoting conditions that enable them to make
healthy choices.102 According to Health Canada, the review of a Class III medical
96 Health Canada, Investigational Testing, supra note 86 at section 5.2.3.
97 Medical Devices Regulations, supra note 68, s. 1, s.v. “near patient in vitro diagnostic
device”.
98 Health Canada, Investigational Testing, supra note 86 at section 1.1.
99 Refers to the accuracy with which a test predicts a clinical outcome.
100 Refers to the likelihood that the use of the test result will lead to an improved health
outcome.
101 Deschênes, supra note 66 at 141.
102 Health Canada, “About Health Canada — Health Products and Food Branch”, online:
<http://www.hc-sc.gc.ca/ahc-asc/branch-dirgen/hpfb-dgpsa/index-eng.php>.
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device licence application takes approximately 60 days.103
The above mentioned process is applicable to the approval of a pharmacoge-
nomic test intended to be sold or imported in Canada. However, Health Canada
recognizes that pharmacogenomic testing is often conducted for exploratory re-
search purposes. In that case, authorization is not required when the test is labelled
“For Research Use Only” and is not labelled or represented for a specific diagnostic
application.104
Another possibility is that the pharmacogenomic test is to be developed for
use in an investigational context, where the objective is to obtain information to
determine its safety and effectiveness prior to marketing.105 To be able to conduct
investigational testing, the manufacturer of the test will have to obtain an authoriza-
tion from Health Canada. As mentioned before, according to section 32(3)(h) of the
Medical Devices Regulations, conducting investigational testing is a pre-requisite
to obtain a Class III medical device licence for near patient in vitro diagnostic de-
vice.106 This means that every time a manufacturer wants to sell a pharmacoge-
nomic test kit in Canada, it has to conduct investigational testing prior to applying
for a licence. According to Health Canada, authorization for investigational testing
is also required when a pharmaceutical company wishes to conduct pharmacoge-
nomic studies during the different phases of drug development.107 The company
could then evaluate and assess the toxicity and efficacy of the new drug compound
prior to marketing it or it could select patients for clinical trials on the basis of their
genotype to ensure that the selected participants react well to the drug. A pharma-
ceutical company could have a great interest in conducting pharmacogenomic stud-
ies during the drug development process so that the drug is marketed with the test
or labelled according to the results of the pharmacogenomic studies, instead of de-
veloping the test once adverse reactions to the drug have been observed in clinical
practice.
The provisions applicable to investigational testing can be found in sections 79
to 88 of the Medical Devices Regulations.108 To obtain authorization for investiga-
tional testing, the manufacturer will have to submit to Health Canada all available
data supporting the analytical validity of the pharmacogenomic test.109 Section 81
of the Medical Devices Regulations indicates that the records of the manufacturer
must contain, among others things: a risk assessment, including the results of any
previous studies and a description of the methods currently used to diagnose the
medical condition for which the investigational testing is being proposed; and a
103 Health Canada, Access to Therapeutic Products: The Regulatory Process in Canada
(Ottawa: Health Products and Food Branch, 2006) at 11 [Health Canada, Regulatory
Process]; Health Canada, Management of Applications for Medical Device Licences
and Investigational Testing Authorizations (Ottawa: Therapeutic Products Directorate,
2001) at section 7 [Health Canada, Management of Applications].
104 Health Canada, Submission of Pharmacogenomic, supra note 32 at section 2.1.2.
105 Health Canada, Investigational Testing, supra note 86 at section 4.1.
106 Medical Devices Regulations, supra note 68, s. 32(3)(h).
107 Health Canada, Submission of Pharmacogenomic, supra note 32 at section 2.1.1.
108 Medical Devices Regulations, supra note 68, ss. 79, 88.
109 Morin, supra note 12 at 21.
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protocol of the proposed investigational testing, including the objective of the test-
ing, the period of time during which the testing will be carried out and a copy of the
patient consent form.110 According to section 83, the authorization will be granted
only if it is determined that no serious danger to the life, health or safety of the
patients can be expected, that the testing is in the best interests of patients and that
the objective of the testing will be achieved.111
The fact that the manufacturer obtained an investigational testing authorization
in order to use the test in the drug development process does not spare the manufac-
turer from having to apply for a Class III medical device licence if it later wishes to
sell or import the test in Canada. The investigational testing authorization only al-
lows the manufacturer to conduct studies on humans to collect evidence on the
safety and efficacy of the pharmacogenomic test. However, the data gathered dur-
ing investigational testing will be considered by the Medical Devices Bureau when
issuing the licence as evidence of the safety and efficacy of the device,112 which
could speed up the licensing process.
Before analyzing the provincial requirements applicable to pharmacogenomic
testing, we would like to highlight an interesting American initiative which could
simplify the process applicable to tests developed during the drug development pro-
cess, so that both products could be licensed at the same time, instead of having to
follow two parallel approval processes. The FDA released, in April 2005, a concept
paper summarizing its preliminary thoughts on how to efficiently co-develop a drug
and a device, such as a pharmacogenomic test.113 This concept paper is still a draft
and the guidance document still has not been released.
The paper provides an optimum process for the development of a drug and test
together. The test is part of drug development from its inception and the clinical
phase of drug development demonstrates the clinical validity and utility of the
test.114 This process would enable the pharmacogenomic test kit to be ready for
approval at the same time as the drug. The FDA recommends co-development
when the pharmacogenomic test and its results are intended to be included in the
drug labelling to determine the dose and to identify patients at risk or patient re-
sponders for clinical and efficacy trials.115 The co-development process would not
be limited to combination products as defined in section 21 CFR 3.2(e) and thus
would apply to drugs and diagnostic tests separately marketed.116 This co-develop-
ment concept paper represents an interesting initiative that could simplify the ap-
110 Medical Devices Regulations, supra note 68, s. 81.
111 Ibid., s. 83.
112 Health Canada, Investigational Testing, supra note 86 at section 4.1.
113 U.S. Department of Health and Human Services, Food and Drug Administration
(FDA), Drug-Diagnostic Co-Development Concept Paper (Draft) (April 2005) at 1
[FDA, Co-Development].
114 Stuart Hogarth, Kathy Liddell, Tom Ling, David Melzer, Simon Sanderson and Ron
Zimmern, Regulating Pharmacogenomics: An Overview of Developments in Various
Countries and Industry Response to Regulatory Incentives: A Report for Health Can-
ada (Cambridge: 2006) at 31.
115 FDA, Pharmacogenomic Data Submissions, supra note 32 at 6.
116 FDA, Co-Development, supra note 113 at 4.
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proval process for drugs and pharmacogenomic tests, in the way that manufacturers
could have both products approved at the same time, without having to go through
different processes. However, as mentioned, the guidance document still has not
been released and it would be interesting to see how the FDA will manage this new
process and what will be expected from the industry.
Health Canada has adopted a similar policy. The Drug and Medical Device
Combination Products Policy has been effective since May 13, 1999, but has since
been modified, and the new version has been effective since March 1, 2006. This
policy aims at ensuring timely access to drug/medical device combination products
and establishes a more efficient submission process for those products.117 Health
Canada recognized the burden created by the fact that drugs and medical devices
had to follow distinct regulatory processes under different regulations and the disin-
centive this burden created to marketing combination products.118 From now on,
the combination products will be subject to either the Medical Devices Regulations
or the Food and Drug Regulations according to the principal mechanism of action
by which the claimed effect of the product is achieved. However, both components
have to meet acceptable standards of safety, efficacy and quality.119 To this day,
the Canadian legislation and regulations still have not been amended to reflect this
policy on combination products.
The problem is that the Canadian policy does not apply to combination prod-
ucts where the drug component and the device component can be used separately,
such as products sold together in procedure packages.120 Health Canada defines a
combination product as a therapeutic product combining a drug and a device com-
ponent where the distinctive nature of the two components is integrated in a singu-
lar product.121 Thus, it seems that this policy does not apply to the case of a drug
sold with a pharmacogenomic test because such tests are kits and each component
is used separately.
(b) Provincial Regulations
According to the Constitution Act, 1867,122 provinces independently regulate
the services delivered by genetic laboratories within their borders through their
power over health services management.123 There is no law in any Canadian prov-
inces specifically regulating laboratories offering genetic testing services, thus they
117 Health Canada, Drug/Medical Device Combination Products (Policy) (Health Canada,
2005) at section 1 [Health Canada, Combination Products].
118 Ibid. at section 2.
119 Ibid. at section 5.
120 Ibid. at section 3.
121 Ibid. at section 4.
122 Constitution Act, 1867, supra note 65.
123 Ibid., ss. 92(7), 92(13), 92(16); See also Anne-Marie Tassé and Béatrice Godard,
L’internationalisation des services génétiques — Analyse comparative des normes de
gouvernance canadiennes, américaines, britanniques et australiennes (Montreal : Thé-
mis, 2009) at 41 [Tassé and Godard, L’internationalisation].
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fall under laws governing medical laboratories.124 Generally speaking, provincial
requirements include the need to hold a licence issued by the government, to obtain
a peer-delivered accreditation, and the need to establish internal and external qual-
ity controls.125 Canadian provinces choose different terms to refer to the notions of
licence and accreditation; for example a licence is called a “permit” in Quebec and
a “certificate of approval” in British Columbia.126 In order to avoid confusion, in
the present text, we will use the vocabulary employed by the Organisation for Eco-
nomic Co-operation and Development (OECD). Thus, the term “licence” will refer
to “a legal permit or a formal permission from a constituted authority or govern-
mental agency to operate a laboratory”127 and the term “accreditation” to “a pro-
cedure by which an authoritative body gives formal recognition that a body is com-
petent to carry out specific tasks,”128 this authoritative body being constituted by
peers.
Because the regulatory framework varies in each province, the present section
of the text will illustrate the requirements of provincial regulations using, as exam-
ples, the rules applicable in Quebec and British Columbia.
Both provinces require laboratories to obtain a licence. As mentioned earlier, a
licence is an official authorization to carry out certain analyses given to laboratories
by a competent administrative provincial authority.129 Although neither province
grants a licence specific to genetic testing services, both grant general licences
which indicate which type of tests the laboratory is authorized to run.130
In Quebec, private laboratories must obtain an operating licence from the pro-
vincial minister of health according to section 31 of the Act Respecting Medical
Laboratories, Organ Tissue, Gamete and Embryo Conservation, and the Disposal
of Human Bodies.131 The minister can refuse to issue a licence if the needs of the
region where the laboratory is to be located do not justify it132 and, if granted, the
licence is issued for one year with the possibility of renewing it every year.133 The
Regulation Respecting the Application of the Public Health Protection Act134 pro-
vides more information on the licence. It states at section 91 that the licence may be
124 Petit, Tassé and Godard, “Empirical Analysis”, supra note 71 at 66.
125 Ibid.
126 The same problem is encountered at the international level, read to this effect: Anne
Marie Tassé, Élodie Petit et Béatrice Godard, “Differences in Regulatory Frameworks
Governing Genetic Laboratories in Four Countries” (2009) 37:2 The Journal of Law,
Medicine & Ethics 351 at 356 [Tassé, Petit and Godard, “Differences in Regulatory
Frameworks”].
127 Organisation for Economic Co-operation and Development (OECD), OECD Guide-
lines for Quality Assurance in Molecular Genetic Testing (OECD, 2007) at 25, online:
<www.oecd.org/dataoecd/43/6/38839788.pdf>.
128 Ibid. at 24.
129 Tassé and Godard, L’internationalisation, supra note 123 at 41.
130 Petit, Tassé and Godard, “Empirical Analysis”, supra note 71 at 67.
131 R.S.Q. c. L-0.2, s. 31 [hereinafter: Act Respecting Medical Laboratories].
132 Ibid., s. 36(3).
133 Ibid., s. 37.
134 R.R.Q. 1981, c. P-35, r. 1.
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issued for three fields of activities: for prosthetic devices or ortheses, medical biol-
ogy examinations and analyses or for radioisotope or radiology examinations.135
When the laboratory conducts medical biology examinations and analyses, the li-
cence is issued for one of four fields of operation: pathological anatomy, biochem-
istry, microbiology, or haematology.136 A laboratory offering pharmacogenomic
testing would fall into the biochemistry category.137 The Regulation Respecting the
Application of the Public Health Protection Act also enacts professional qualifica-
tion requirements for the director and the staff of the laboratory at sections 132 and
133.138 Finally, section 136 stipulates that all work carried out by a medical biol-
ogy laboratory must be in response to a prescription signed by a professional em-
powered to do so under the regulations of his or her professional corporation, un-
less it is in response to a request made by a health services and social services
institution.139
Public laboratories in Quebec are not subject to the Act Respecting Medical
Laboratories because the definition of “laboratory” in section 1 b) excludes labora-
tories operated inside a facility maintained by a public institution.140 Nevertheless,
this does not mean no licence is necessary. The Act Respecting Health Services and
Social Services141 requires that hospital centres hold a license issued by the min-
ister.142 This licence draws up a list of the facilities at the disposal of the institu-
tion143 and the activities of the licence holder must be carried out within the scope
of the licence.144 Thus, public laboratories themselves do not have to hold a li-
cence, but the institutions where the laboratories are operated must obtain one. Ac-
cording to section 442, the licence issued to an institution is valid until modified,
cancelled, or withdrawn.145 The Permits for Institutions (Issue and Renewal) Regu-
lation146 provides additional information to obtain a licence; in particular, its
schedule provides the application form.147
In British Columbia, a licence to open a laboratory is granted by the Medical
Services Commission under section 33(1) of the Medicare Protection Act.148
135 Ibid., s. 91.
136 Ibid., s. 93.
137 Ministry of Health and Social Services, Laboratoire de biologie médicale — Mesure de
la production (Quebec : Direction des communications du ministère de la Santé et des
Services sociaux, 2003) at 5-6; Deschênes, supra note 66 at 69.
138 Regulation Respecting the Application of the Public Health Protection Act, supra note
134, ss. 132, 133.
139 Ibid., s. 136.
140 Act Respecting Medical Laboratories, supra note 131, s. 1(b).
141 R.S.Q., c. S-4.2.
142 Ibid., s. 437.
143 Ibid., s. 440.
144 Ibid., s. 444.
145 Ibid., s. 442.
146 O.C. 1372-84, 1984, G.O. 2, 2370.
147 Ibid., Sch. I.
148 Medicare Protection Act, R.S.B.C. 1996, c. 286, s. 33(1).
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Under section 40 of the Medical and Health Care Services Regulation,149 the Med-
ical Services Commission can not issue a licence unless it is satisfied that there is
sufficient medical need for the proposed services and that the quality of diagnostic
services will be maintained at a high level.150 Additional conditions for the issu-
ance of a license are provided at section 43.151 For example, the laboratory has to
comply with diagnostic protocols and guidelines adopted and communicated by the
Medical Services Commission.152 The laboratory also has to maintain its standards
of testing and analysis, its number of qualified personnel, its level of supervision by
medical personnel and the range of services it provides at the level the Medical
Services Commission considers satisfactory.153
Besides the obligation to hold a licence, laboratories in Quebec and British
Columbia can be required to obtain an accreditation from an independent body that
certifies that they are competent to carry out the analyses they offer.154 This mech-
anism aims at ensuring the safety and quality of the tests offered and consists of an
evaluation by independent professionals of the operations and practices of the labo-
ratory, of its equipment, technical operating conditions, and of the competence of
its personnel.155 Many accreditation bodies are presently working on the imple-
mentation of documents from the International Organization for Standardization
(ISO).156 In Canada, each accreditation body develops its own standards for ac-
creditation.157 However provincial accreditation standards are all inspired by the
ISO 15189, Medical laboratories — Particular requirements for quality and com-
petence standard and its Canadian version CAN/CSA Z15189-03, Medical labora-
tories Particular requirements for quality and competence, which imposes two
types of requirements: those related to the management of the laboratory, and the
technical requirements concerning the personnel, the environment, the material and
the quality of the procedures.158 In Canada, only five provinces have specific ac-
creditation bodies for medical laboratories: Alberta, British Columbia, Manitoba,
Ontario, and Saskatchewan.159
In Quebec, the Act Respecting Medical Laboratories contains no mention that
an accreditation is required for private laboratories, except for medical imaging lab-
oratories.160 As for public laboratories, section 107.1 of the Act Respecting Health
Services and Social Services provides that the institutions in which they are oper-
149 B.C. Reg. 426/97.
150 Ibid., s. 40.
151 Ibid., s. 43.
152 Ibid.
153 Ibid.
154 Hui Li and Khosrow Adeli, “Laboratory Quality Regulations and Accreditation Stan-
dards in Canada” (2009) 42 Clinical Biochemistry 249 at 249.
155 Petit, Tassé and Godard, “Empirical Analysis”, supra note 71 at 67-68.
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ated must be accredited, every three years, for the services they offer.161 The law
does not specify the accreditation body; institutions have the choice between two
accreditation bodies recognized by the ministry of Health and Social Services: the
Canadian Council on Health Services Accreditation and the Conseil québécois
d’agrément.162 Since 2005, the Circulaire 2005-007, Conformité des laboratoires
de biologie médicale à la norme CAN/CSA-15189 “Laboratoire d’analyses de bio-
logie médicale — Exigences particulières concernant la qualité et la compétence”
requires that public laboratories conform with the national accreditation standard
CAN/CAS-Z15189-03.
In British Columbia, laboratories must be accredited under section 121 of the
Medical Practitioners Act.163 Laboratories are accredited by the College of Physi-
cians and Surgeons, and more specifically by the Diagnostic Accreditation Pro-
gram.164 The granting of an accreditation is subject to section 125 of the Rules
Made Under the Medical Practitioners Act and the accreditation is delivered for a
maximum of five years.165
Finally, the last provincial requirement concerning medical laboratories is the
establishment of internal and external quality controls to guarantee the quality and
reliability of the data produced. Generally, internal quality control is the responsi-
bility of laboratory directors, whereas external quality control is exercised by an
independent and external assessment of the accuracy of the analyses usually man-
aged by the same body responsible for accreditation.166
In Quebec, internal quality control of private laboratories is regulated by sec-
tions 139 and 140 of the Regulation Respecting the Application of the Public
Health Protection Act, which stipulate that the director of the laboratory must es-
tablish quality control programs complying with standards generally recognized in
hospital centre laboratories and a program for quality control of examinations or
analyses made.167 Concerning external quality control, the provincial Ministry of
Health entrusted the Laboratoire de santé publique du Québec with the responsibil-
ity to put in place a quality control program for medical biology analyses.168 Sec-
tion 140.1 of the Regulation Respecting the Application of the Public Health Pro-
tection Act requires that the director of a private laboratory participate in the quality
control programs established by the Laboratoire de santé publique du Québec.169
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Those programs pertain to the equipment, technical operation, and sanitary condi-
tions of the laboratory and the qualifications of the staff. Incidentally, sections 116
to 120 provide rules concerning the quality of the equipment used and sanitary
measures.170
In British Columbia, sections 126 and 128 of the Rules Made Under the Medi-
cal Practitioners Act provide that to maintain accreditation, the laboratory shall
comply with satisfactory quality controls and must meet the standards regarding its
personnel, equipment, space, and safety procedures.171 Moreover, section 39(1)(i)
of the Medical and Health Care Services Regulation states that for a licence appli-
cation, a list and description of quality control procedures and programs planned
have to be submitted.172
At the provincial level, pharmacogenomic testing is not subject to specific reg-
ulations. The control carried out is very different from the one exercised by Health
Canada on medical devices, because the provincial requirements are more focused
on the quality and the proper functioning of the laboratory rather than on the
clinical validity and utility of the tests.173 Provincial requirements are less stringent
than federal ones, but it has to be remembered that a laboratory can only conduct
the tests authorized in its licence. Thus, it is expected that there is some control
over the ability of the laboratory to run the tests authorized, but less on the clinical
validity and utility of the tests.
(c) Difficulties Faced By the Industry in Relation with the Approval
Process
Companies that develop pharmacogenomic tests are faced with many difficul-
ties at the regulatory level that affect the availability of pharmacogenomic services
on the market. The main problem facing manufacturers is gathering sufficient sci-
entific data to demonstrate the efficacy, clinical validity, and utility of the tests.
Even if pharmacogenomics shows great promise, it is still considered to be in
its infancy. Clinical validation of pharmacogenomic tests is still difficult to demon-
strate due to the fact that the genotype/phenotype relationship is complex: indivi-
dual variations in drug response are often linked to more than one gene and to non-
genetic factors such as the age of the patient, the other medications he or she might
be taking, and his or her state of health, environment, and diet.174 Thus,
pharmacogenomics is a probabilistic science and, because factors other than geno-
type can affect the way a patient will respond to a certain drug, it could be difficult
to affirm that we could rely only on the results of a given pharmacogenomic test to
make clinical decisions affecting their health. As a result, the benefits of
170 Ibid., ss. 116–120.
171 Rules Made Under the Medical Practitioners Act, supra note 163, ss. 126, 128.
172 Medical and Health Care Services Regulation, supra note 149, s. 39(1)(i).
173 Deschênes, supra note 66 at 74-75; Petit, Tassé and Godard, “Empirical Analysis”,
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174 Hogarth, Liddell, Ling, Melzer, Sanderson and Zimmern, supra note 114 at 35;
Buchanan, Califano, Kahn, McPherson, Robertson and Brody, “Ethical issues”, supra
note 49 at 3-4.
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pharmacogenomics should not be overstated.175 In the United States, the FDA ob-
serves that most of the current pharmacogenomic tests are insufficiently well-de-
veloped to be used in regulatory decision-making.176 To establish that a test has
clinical validity, the manufacturer has to carry out clinical studies that can be costly
and time-consuming due to the sometimes low number of individuals with a partic-
ular characteristic drug response.177
Clinical utility is also an obstacle to the development of pharmacogenomic
tests: it is not sufficient that a test detect a given polymorphism; the presence of
that polymorphism must also have medical importance.178 Another important fact
to consider relates to the existence of other preventive options: even if a
pharmacogenomic test predicting an adverse reaction is produced, the drug to
which it is related could be the only one available for the treatment of a serious
disease. If no other treatment is available, what will be the impact of the results?
Medical practitioners and patients will then be faced with the decision whether to
take the treatment and accept its side effects or inefficiency, or to refuse the treat-
ment with no other options from which to choose.
Pharmacogenomics also creates a problem of reduced revenues that result
from market segmentation which may make the costs of pharmacogenomic re-
search and development unjustifiable.179 Even if nowadays the “blockbuster era” is
at its end,180 pharmacogenomics will likely lead to a further fragmentation of the
market. This could discourage private research and development in the field, since
drug companies could be resistant to producing expensive drugs that will be sold to
a smaller portion of the population. One of the dangers is thus that groups charac-
terized by less-profitable genotypes become therapeutic orphans.181 In other words,
drug companies could neglect the development of drugs addressed to less common
genotypes because they would be less lucrative in terms of sales revenue (the mar-
ket being even smaller than for other drugs).182 The term “orphan drug” is usually
assigned to pharmaceuticals for rare diseases, but the results would be the same in
the case of pharmacogenomics.183 One solution to this problem could be the adop-
tion, by government, of incentives meant to stimulate research and development in
less profitable fields of research. Such measures could be similar to those taken in
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the United States and the European Union concerning drugs treating rare
diseases.184
III. DISCUSSION
Pharmacogenomics is expected to benefit drug companies, patients and regu-
latory bodies by improving and speeding up drug research and development, the
approval process and post-marketing drug surveillance. Pharmacogenomics is also
likely to change clinical practice by allowing the customization of treatments to
individual genetic characteristics and by producing safer and more efficient drugs
to minimize the occurrence of adverse drug reactions. A pressing question is
whether, considering the benefits pharmacogenomics could provide to the practice
of medicine and pharmacy, the current regulatory framework is sufficiently adapted
to promote the development of pharmacogenomics or instead inhibits the develop-
ment of pharmacogenomic tests. Should a simpler process be instituted in order to
make the tests more readily accessible to patients and to encourage the use of
pharmacogenomic testing in the development of drugs?
In our opinion, the question of whether the regulatory framework applicable to
pharmacogenomic tests is appropriate pertains to considerations which are more
related to the federal process than the provincial one. As seen earlier, the provincial
regulations are more aimed at ensuring that the laboratories can carry out the tests
they offer to the public with the best quality possible than at ensuring the clinical
validity and utility of the pharmacogenomic tests.
At the federal level, some fast tracking mechanisms exist, but they are not
adapted to the case of pharmacogenomic testing. Sections 69 to 78 of the Medical
Devices Regulations provide the requirements concerning special access to medical
devices.185 They allow for faster access to a medical device for emergency use or if
conventional therapies have failed, are unavailable or are unsuitable.186 The appli-
cation has to be made by a health care professional.187 The minister will grant the
authorization if the benefits outweigh the risks associated with the use of the de-
vice, if the health or safety of patients will not be unduly affected and if no licensed
device is available in Canada for the needs of the patient.188 The authorization will
specify the number of units of the device authorized and the name of the health care
professional to whom the manufacturer may sell the device. Another fast tracking
mechanism provided by the law is the priority review process. An interim policy
concerning priority review of medical devices licence applications was released by
Health Canada in 2000.189 Priority review will be granted if the medical device is
intended for the diagnosis or treatment of a serious, life-threatening disease, or
184 Ibid. at 229-230; Issa, supra note 6 at 305-306.
185 Medical Devices Regulations, supra note 68, ss. 69–78.
186 Ibid., s. 69(2).
187 Ibid., s. 71.
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189 Health Canada, Interim Policy on Priority Review of Medical Device Licence Applica-
tions Policy (Interim policy) (Ottawa: Therapeutic Products Programme, 2000) [Health
Canada, Priority Review].
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when there is clinical evidence that the device provides an effective treatment of a
disease for which no medical device is available in Canada or a significant risk-
benefit improvement for a disease not adequately managed by existing products.190
Neither program is suited to pharmacogenomic testing because pharmacogenomic
tests are not used as treatments, but rather as tools that allow choosing a more ap-
propriate treatment. Thus, it can be difficult to demonstrate that pharmacogenomic
tests are needed for emergency use or to treat a disease in cases where no other
treatment options are available. Also, there has to be proof that the test will be
useful, which boils down to showing evidence of the clinical validity and utility of
the test. Thus, those programs do not spare the manufacturer from the difficulties
mentioned earlier.
The federal process applicable to the approval of pharmacogenomic tests in-
tended to be sold or imported as kits in Canada requires the manufacturer to assess
scientific and medical evidence of the safety, efficacy, and validity of the tests they
propose to offer. The time taken by Health Canada to review the licence application
seems adequate (around 60 days),191 but the process of gathering all the evidence
needed to submit an application can be a lengthy one because of the difficulties
faced by the industry we mentioned earlier (e.g. demonstrating clinical validity and
utility). But even if the manufacturers are faced with the difficulty of providing this
type of evidence given the potential benefits of pharmacogenomics, it is essential
that the sensitivity, specificity, and positive predictive value of the tests be estab-
lished.192 Pharmacogenomic tests have to be reliable to avoid mistakes and poor
outcomes for patients.193 In other words, pharmacogenomic tests will only achieve
the great benefits their proponents expect them to have if they are valid and use-
ful.194 Otherwise, it would be difficult to claim that pharmacogenomics will benefit
patients and drug research and development.
Thus, the current regulatory requirements seem adequate because, according
to the regulations, where evidence of the validity and the usefulness of a new test
has been gathered, the licence should be granted. If all the evidence has been sub-
mitted, then it is possible to obtain a licence from Health Canada in a reasonable
timeline. Pharmacogenomic impacts do not require the current federal process for
the approval of pharmacogenomic tests to be simplified. Rather they require that
the validity of the tests be scientifically established so that clinical decisions can be
made from the results they provide. Because it is expected that many pharmacoge-
nomic tests will be developed in the near future, there is a need for an efficient and
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ethical regulatory oversight of the validity and utility of the tests.195
Moreover, if manufacturers do not want to go through the federal process,
they can always offer their pharmacogenomic tests as laboratory services, instead
of selling them as test kits. They will then have to conform with provincial require-
ments that are far less stringent on the question of clinical validity and utility of the
tests. However, in this situation, the reviewed American literature raises concerns
that the regulatory oversight of pharmacogenomic tests might not be sufficient to
protect the public against pharmacogenomic tests of poor quality.196
In our opinion, the federal requirements seem appropriate for pharmacoge-
nomics. The provincial ones do not, however, because they do not focus enough on
the clinical validity and utility of the tests carried out by medical laboratories. Al-
though the current federal process should not be substantially modified, some im-
provements could be brought to the system. One of them could be to simplify the
process applicable to pharmacogenomic tests developed during the drug develop-
ment process, so that both products could be licensed at the same time by Health
Canada, instead of having two parallel approval processes to follow. We examined
the American Drug-Diagnostic Co-Development Concept Paper earlier in our anal-
ysis.197 As we indicated, the final guidance document still has not been released by
the FDA. It will be interesting to see what form this initiative will take and if
Health Canada will follow in the footsteps of the FDA. Currently, the Canadian
Drug and Medical Device Combination Products Policy does not apply to combi-
nation products where the drug component and the device component can be used
separately, such as the case of a drug sold with a pharmacogenomic test.198
CONCLUSION
The fact that manufacturers are facing difficulties in demonstrating the clinical
validity and utility of the pharmacogenomic tests they are developing does not nec-
essarily mean the federal requirements of Health Canada should be relaxed. When
the studies in the research context show the potential of a pharmacogenomic test to
be valid and useful, investigational testing has to be conducted to demonstrate that
the research findings can translate into clinical practice. When there is sufficient
evidence of the analytical validity, the clinical validity and the clinical utility of the
test, Health Canada will issue a licence to the manufacturer within an acceptable
timeline. Considering the promises of pharmacogenomics and the fact that it can
affect health outcomes of patients, it is of the utmost importance that this type of
evidence be provided by the manufacturer to protect the patients from ineffective
tests that could adversely impact human health. In order to benefit from a
pharmacogenomic test, it has to be effective and useful. Thus, a mechanism fast
tracking the approval of pharmacogenomic tests would not necessarily provide a
solution to the problems faced by the industry because proof of the validity and
195 Robertson, Brody, Buchanan, Kahn and McPherson, “Pharmacogenetic Challenges,”
supra note 50 at 159.
196 Buchanan, Califano, Kahn, McPherson, Robertson and Brody, “Ethical Issues”, supra
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197 FDA, Co-Development, supra note 113 at 1.
198 Health Canada, Combination Products, supra note 117 at section 3.
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utility of the tests would still be needed. One acceptable mechanism that could
speed up the process would be a policy on the co-development of drugs and medi-
cal devices. This would allow the drug and the pharmacogenomic test to be ap-
proved at the same time by Health Canada in instances where a test is used during
the drug development process. It could also expedite and streamline the process by
requiring one licence application, rather than two. Such a policy would not relax
the need for the manufacturers to demonstrate the analytical validity, clinical valid-
ity, safety, and clinical utility of both products. Aside from this co-development
mechanism, financial incentives given by the government could also promote the
faster development of pharmacogenomic tests. Indeed, the economic costs of devel-
oping pharmacogenomic tests are high and, considering the fact that those tests
would fragment the market and reduce the revenues from drug sales, manufacturers
and drug companies are not sufficiently encouraged to develop such tests. As a
society, we might need to find a way to stimulate research and development in this
important research field in order to one day profit from more “personalized”, safer
and more efficient medicine. Indeed, the fact that manufacturers have the tendency
to develop and approve their pharmacogenomic tests outside of Canada and that
most of these tests are marketed as laboratory services or “home-brewed” tests
could be of concern to Canadians and raise important issues relating to timely ac-
cess to safe medicines. 
